BRAAVE2020. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in black americans with HIV-1: a randomized phase 3b, multicenter, open-label study.
Hagins D., Kumar P., Saag M., Wurapa AK., Brar I.,Berger D., Osiyemi O., Hileman CO., Ramgopal MN., McDonald C., Blair C., Andreatta K., Collins SE., Brainard DM., Martin H., BRAAVE2020 Investigators. J Acquir Immune Defic Syndr 2021;88(1):86-95. doi: 10.1097/QAI0000000000002731.